Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valaciclovir in Early Alzheimer's Disease (VALZ-Pilot)
NCT02997982Phase 2Completed
- Start
- Dec 2016
- Primary completion
- Mar 2020
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of valaciclovir in Alzheimer's disease (AD). Primary endpoint: Cerebrospinal fluid Total Tau at Day 28. Started Dec 2016; status: completed.
02
Drugs
valaciclovir
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02997982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02997982.